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Expression profiles of p53/p73, 
NME and GLI families in metastatic 
melanoma tissue and cell lines
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Unlike other tumours, TP53 is rarely mutated in melanoma; however, it fails to function as a tumour 
suppressor. We assume that its functions might be altered through interactions with several families 
of proteins, including p53/p73, NME and GLI. To elucidate the potential interplay among these families 
we analysed the expression profiles of aforementioned genes and proteins in a panel of melanoma cell 
lines, metastatic melanoma specimens and healthy corresponding tissue. Using qPCR a higher level 
of NME1 gene expression and lower levels of Δ40p53β, ΔNp73, GLI1, GLI2 and PTCH1 were observed 
in tumour samples compared to healthy tissue. Protein expression of Δ133p53α, Δ160p53α and 
ΔNp73α isoforms, NME1 and NME2, and N′ΔGLI1, GLI1FL, GLI2ΔN isoforms was elevated in tumour 
tissue, whereas ∆Np73β was downregulated. The results in melanoma cell lines, in general, support 
these findings. In addition, we correlated expression profiles with clinical features and outcome. Higher 
Δ133p53β and p53α mRNA and both GLI1 mRNA and GLI3R protein expression had a negative impact 
on the overall survival. Shorter overall survival was also connected with lower p53β and NME1 gene 
expression levels. In conclusion, all examined genes may have implications in melanoma development 
and functional inactivity of TP53.
Malignant melanoma remains the most aggressive and treatment-resistant form of skin cancer with increasing 
incidence1. Although recent advances in melanoma therapy improve the overall patient survival, they are still 
hampered by rapid and pervasive treatment resistance. Thus, novel molecular approaches that would contribute 
to a better understanding of the disease should be deployed.
p53 plays a substantial role in the response to stress by coordinating diverse signalling pathways, thereby 
preventing the tumour formation. Unlike other cancers, in metastatic melanoma TP53 gene is relatively rarely 
mutated. However, it fails to function as a tumour suppressor and reduced levels of p53 contribute to aggressive-
ness and resistance to therapy2. Several diverse mechanisms of p53 inactivation in melanomagenesis have been 
proposed. The most common mechanisms include mutations of cyclin-dependent kinase inhibitor CDKN2A 
(encoding for both p16INK4A and p14ARF, which inactivates MDM2) and MDM2 (negative regulator of p53) 
overexpression, activation of iASPP (inhibitor of apoptosis stimulating protein of p53) or silencing of the TP53 
gene by epigenetic mechanisms2–5. However, the later phenomenon has not been fully understood.
The p53 family comprises of p53, p73 and p63. Transcription from alternative promoters, alternative splicing 
and diverse translation initiation sites contribute to the family complexity6,7, and twelve protein isoforms with 
different N- and C-termini are encoded by the single TP53 gene (Fig. 1)8. The diversity in structure leads to diver-
sity in subcellular localization, and consequently in various biochemical/biological activities which are cell-type 
dependent. Finally, p53-mediated cell response is the sum of the activities which results from co-expressed p53 
isoforms8. Currently, the evidence explaining the involvement of p53 isoforms in tumour formation is still limited.
Likewise, two main groups of p73 isoforms with different N-termini are produced: the TAp73 isoforms 
with the entire TAD and the N-terminally truncated isoforms, ΔNp73, lacking TAD and acting, mainly, as 
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dominant-negative inhibitors towards p53 and TAp739. In contrast to p53, p73 is essentially never mutated in 
cancer, but it is overexpressed6,10.
Most of the p53 family isoforms possess the ability to interact between themselves forming heterotetramers 
and compete for DNA binding, so the overall activity of p53/p73 proteins is a result of the ratio between the dif-
ferent isoforms. Thus, in melanoma it has been found that p63 interacts with p53 influencing its tumour suppres-
sive role11, while the Δ40p53 isoform forms heterotetramers with p53 modifying downstream p53 target genes 
and promoting apoptosis over cell cycle arrest12. However, we assume that p53 function in metastatic melanoma 
might be altered through interactions with some other proteins, like NME and GLI families of proteins.
The NME (NM23, NDPK, Awd) gene/protein family consists of ten members named after the first one identi-
fied, NME1/NM23-H1/NDPKA13, which is considered to be a metastasis suppressor gene. Besides its enzymatic 
activity (nucleoside-diphosphate kinase), the NME proteins have been assigned several additional biochemical 
functions such as transcription regulators, protein kinases and DNases14. A connection between NME expression 
and melanoma formation or metastasis has been described in several reports15–17. Although the investigations 
were primarily focused on NME1 as a primary metastasis suppressor, some data on NME2 in murine and human 
melanoma are also available18–20. Lately, several independent studies suggest there is either a direct or indirect 
connection between p53 and NME gene/protein family members21–23.
The Hedgehog-GLI (HH-GLI) signalling pathway plays a vital role during embryonic development, stem and 
progenitor cell maintenance, and carcinogenesis. Binding of the Hedgehog (HH) ligand to the receptor Patched 
(PTCH1) triggers the cascade leading to the activation of transcription factors GLI1, GLI2 and GLI3. They regu-
late cell proliferation, cell cycle regulation, adhesion, epithelial-mesenchymal transition, self-renewal and path-
way autoregulation (PTCH1 and GLI1 genes)24. GLI1 is the exclusive activator, while GLI2 and GLI3 are cleaved 
into repressor forms when the HH signal is not present25. PTCH1, GLI1 and GLI2 overexpressions have been 
associated with melanoma progression and invasive and metastatic phenotype26,27. The HH-GLI pathway is also 
governed by non-HH signalling pathways by interactions with other pathways, including p5328–30. p53 nega-
tively inhibits GLI1-driven neural stem cell self-renewal, cell proliferation and tumour growth and, in turn, GLI1 
represses p5331,32. The balance between p53 and GLI1 activities appears to be critical: loss of p53 in cancer could 
enable activities of GLI1 and GLI232,33, while repression of GLI3 activity potentiates p53-dependent cell growth 
inhibition in colon cancer cells34.
The aim of this work is to study the potential interplay between these three pathways involved in melanoma 
development and progression. To gain this knowledge, it was necessary to determine the expression pattern of a 
range of isoforms of the above mentioned proteins, which have not been systematically investigated in melanoma 
so far. In all the studies performed so far on metastatic melanoma, p53 isoforms’ expression was determined 
in cell lines, not in surgical tissue samples, while GLI isoforms have not been examined at all. Therefore, we 
investigated the expression of three groups of genes and proteins and their correlation to clinicopathological 
characteristics.
Results and Discussion
Gene expression in metastatic melanoma tissue samples and cell lines. Gene expression analysis 
was performed on 32 tumour tissue samples and 19 healthy skin samples from the same patients. The TP53 isoforms 
were pre-amplified in two separate pre-amplification reactions, giving a “long” and “short” template for quantitative 
real-time PCR (qPCR) amplification and analysis. The mean relative expression of “long” TP53 isoforms in tumour 
tissue, ranked from the highest to the lowest, was as follows: p53α > p53β > p53ɣ > ∆40p53α > ∆40p53β > ∆40p
Figure 1. Scheme of the TP53 gene (a) and the protein isoforms (b). The colour of the protein domains 
matches the corresponding exon. Black boxes represent noncoding sequences, whereas coding sequences are 
in grayscale. The TP53 gene is composed of 11 classical exons and alternative exons (9 β and γ). Furthermore, it 
contains an internal promoter (P2), alternative splice variants (Δ40, β, γ) and internal initiation of translation 
sites (ATG1, ATG40, ATG133, ATG160). The p53 protein is composed of several domains - transactivation 
domain (TAD, which actually include two different domains, TAD1 and TAD2), the DNA-binding domain 
(DBD) and the nuclear localization signal (NLS). Twelve protein isoforms with different N- and C-termini are 
encoded by the human TP53 gene – alternative splicing of human intron 2 gives rise to Δ40p53 (truncated 
transactivation domain, TAD) and intron 9 to α, β and γ isoforms; the usage of the alternative promoter 
produces Δ133p53 and Δ160p53 (both lacking the entire TAD), while alternative translation initiation site 
produces Δ40p53 and Δ160p53.
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53ɣ. Ranking of the mean relative expression of “short” TP53 isoforms was: ∆133p53α > ∆133p53β > ∆133p53ɣ. 
Only one out of nine TP53 isoforms was significantly downregulated in tumour tissue (∆40p53β, p = 0.017) 
(Fig. 2). A similar trend was observed for the ∆40p53ɣ isoform but without statistical significance (p = 0.054). The 
expression levels of the studied genes were confirmed using a panel of eight melanoma cell lines. We have observed 
almost a perfect match of the mean gene expression levels in cell lines and metastatic melanoma tissues with a small 
deviation of ∆40p53β and ∆40p53ɣ and the shortest, Δ133p53γ. The role of ∆40p53β was not particularly studied 
so far. However, based on obtained data, it has to be taken into account.
Previous clinical studies have reported the expression of TP53 isoforms in several tumour types, confirming 
that small molecular weight p53 isoforms might play an important role in tumorigenesis12,35–40. Avery-Kiejda 
and collaborators described that p53β and ∆40p53 mRNAs were expressed at higher levels than p53α in most 
melanoma cell lines examined, compared to fibroblasts and melanocytes, suggesting that their expression may 
play a role in melanoma development41. However, none of these aforementioned studies applied a sophisticated 
approach in which qPCR was performed as a nested reaction following initial RT-PCR amplification.
The remaining genes were analysed using standard TaqMan assays. We were able to determine the gene 
expression of two cancer-relevant TP73 isoforms, TAp73 and ∆Np73. Unexpectedly, the expression of full length 
isoform TAp73 was higher than ∆Np73. Further, ∆Np73 expression was significantly downregulated in meta-
static melanoma tissue (p < 0.0001) (Fig. 3). There is a paucity of studies that have analysed the p73 isoforms’ gene 
expression in melanoma. The only detailed study of the expression and effect of particular p73 isoforms in met-
astatic melanoma showed overexpression of TAp73, Ex2p73 and Ex2/3p73 (spliced transcripts derived from the 
first promoter), whereas ΔNp73 was the predominant isoform in benign nevi42, which is in line with our findings.
In our study a significant downregulation of GLI1 (p = 0.001), GLI2 (p < 0.0001) and PTCH1 (p = 0.006) in 
tumour tissue was observed. Several studies have shown upregulation of HH-GLI signalling in melanoma. A 
study on clinical samples showed that melanoma cells express SHH, GLI1 and PTCH1 mRNA, but the surround-
ing stroma does not26. Another study showed upregulation of SMO, GLI2 and PTCH1 mRNA in a subset of mela-
noma cell lines43. GLI2 was found to be associated with invasive and metastatic phenotype in melanoma. Tumours 
with high GLI2 expression metastasize to the bone more quickly than tumours with low GLI2 expression27.
Several groups of authors analysed the correlation between the RNA and protein levels of NME and their 
metastatic potential with heterogenous results15–17,44,45. Although there has been evidence that the NME1 RNA 
Figure 2. Relative expression levels of TP53 isoforms analysed by pre-amplification followed by qPCR using 
SYBR Green dye. The expression was normalized to the expression level of total TP53. Results are presented 
in a log scale, the bars represent interquartile range and the black triangle represents median value. *Denotes 
p < 0.05.
4Scientific RepoRtS |         (2019) 9:12470  | https://doi.org/10.1038/s41598-019-48882-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
levels can be elevated while the protein levels are low due to protein degradation in invasive melanoma cells46, in 
our experiments NME1, as well as NME2, was significantly up-regulated on both, the RNA and protein level in 
tumours compared to healthy tissue (p = 0.041) (Figs 3, 5 and Supplementary Fig. S1).
The mean expression of TP73, NME and HH-GLI signalling pathway genes in a panel of eight melanoma cell 
lines almost completely match the mean expression in metastatic melanoma tissue (Fig. 4a). The expression lev-
els of TP53 isoforms in melanoma cell lines showed some differences. It can be observed that ∆40p53 isoforms, 
Figure 3. Relative expression of genes analysed by TaqMan assays. The expression was normalized to the 
expression level of GUSB and TBP (2−ΔCt). Results are presented in a log scale, the bars represent interquartile 
range and black triangle represents median value. *Denotes p < 0.05.
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particularly the shortest Δ133p53γ, showed lower expression levels in cell lines compared to tumour tissue sam-
ples (Fig. 4b). TP53 isoforms were not expressed at all in LM6 (4405 P) cell line probably due to the lack of TP53 
locus47.
Protein expression in metastatic melanoma tissue samples and cell lines. In 30 paired tumour 
and healthy skin tissue samples we quantified the expression of 18 proteins in total: six p53 isoforms differing 
by both N- and C-termini (p53α, p53β, ∆40p53α, ∆133p53α, ∆133p53β and ∆160p53α); four p73 isoforms 
(TAp73α, TAp73β, ∆Np73α and ∆Np73β); NME1 and NME2; two GLI1 isoforms (N′ΔGLI1 and GLI1FL, 
molecular weights 130 and 160 kDa, respectively); two GLI2 isoforms (GLI2ΔN and GLI2FL, molecular 
weights 133 and 250 kDa, respectively), GLI3 activator (GLI3A, 190 kDa) and GLI3 repressor (GLI3R, 83 kDa). 
Summary of the results comprising the number and percentage of positive healthy and tumour samples is shown 
in Supplementary Table S1. When compared with healthy tissue, eight proteins showed statistically significant 
higher expression in tumours: both GLI1 isoforms (N′ΔGLI1, p = 0.030; GLI1FL, p = 0.002), GLI2ΔN isoform 
(p < 0.0001), both NME1 and NME2 (p = 0.0001 and p < 0.0001, respectively), ∆Np73α (p = 0.020) and two 
p53 isoforms - ∆133p53α and ∆160p53α (p = 0.0002 and p = 0.001, respectively). Conversely, the expression of 
∆Np73β isoform was significantly downregulated in tumour tissue (p = 0.005) (Fig. 5). Further, the mean expres-
sion levels in a panel of eight melanoma cell lines were investigated (Supplementary Fig. S1) and when compared 
with metastatic melanoma tissue, almost perfect match of mean expression levels was observed with exception of 
Δ133p53β, ΔNp73 and GLI3R (Fig. 6).
Due to the different site of the translation initiation, the presence of all known protein isoforms can be deter-
mined only by Western blot using specific antibodies that recognize a particular set of isoforms and p53/p73 
standards (cells transfected with the specific isoform) helped to identify every single isoform (Supplementary 
Fig. S1). Previous studies reported wild type p53 overexpression in melanoma cell lines and tissue samples48,49. 
However, in these studies the authors used immunohistochemical analysis in which it was impossible to distin-
guish the specific isoforms. Therefore, our study is the first detailed study of p53 isoform expression in metastatic 
melanoma tissue.
Using this approach, ΔNp73α protein was significantly more expressed in the metastatic melanoma than in 
healthy tissue as compared to gene expression analysis. These inconsistencies between gene and protein expression 
are not unusual, since post-transcriptional regulation plays an important role in modification of proteins. Also, the 
experimental approach we used enabled us to distinguish the isoforms more precisely. Overexpression of total p73 
in invasive cutaneous melanoma was recently shown using immunohistochemistry50. Overexpression of ΔNp73 is 
reasonable considering that ΔNp73 drives migration and invasion of nonmetastatic melanoma cells51.
As mentioned earlier, our results show elevated NME1 and NME2 mRNA and protein levels in metastatic 
melanoma although we would expect them to drop in metastasis due to the proposed role of NME as a metasta-
sis suppressor. However, the mechanism by which NME contributes to tumour progression seems to be rather 
complex and does not rely solely on the rate of their expression. It has been reported that the NME1 content 
Figure 4. Comparison of relative expression values for tumour samples (solid line) and melanoma cell lines 
(dashed line) normalized to the expression level of GUSB and TBP. (a) Mean expression values of TP53 
isoforms analysed by pre-amplification and SYBR Green RT-qPCR. (b) Mean expression of other tested genes 
analysed by TaqMan assays.
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significantly varies in different cell populations within a tumour tissue sample. As an example, it has been sug-
gested by Martinez and co-workers that NME1 could be less expressed in the invasion front compared to other 
cellular populations within the tumour mass52 which would probably be possible to detect immunohistochemi-
cally but not using Western blot, as was the case in our study.
Again, we found a discrepancy between gene and protein expression regarding HH-GLI pathway components. In 
recent years it has become clear that the GLI code is more complex than previously thought, with five known isoforms 
Figure 5. Expression of p53, p73, NME and GLI proteins. Proteins were analysed by PAGE, Western blot and 
densitometry with samples normalized to actin staining, followed by Wilcoxon paired sample analysis. P-values 
for proteins with significant difference in expression between tumour and healthy tissue are marked in bold. 
*Denotes p < 0.05.
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of GLI1, five of GLI2 (two of which with repressive activity), and two of GLI3, the GLI3A and GLI3R (reviewed in53) 
which can be distinguished only by Western blot analysis. Interestingly, Roessler and collaborators have demonstrated 
that GLI2ΔN is up to 30-fold more potent than the full length GLI254. GLI2ΔN can induce genomic instability by 
interfering with the cell cycle, acting through downregulation of mitosis regulators 14-3-3σ and p21WAF1/CIP1 55.
Correlation of gene and protein expression. Several TP53 isoforms were found to be correlated on 
the level of gene expression. A very strong correlation (ρ > 0.8) was found between Δ40p53γ and Δ40p53β, 
Δ133p53γ and Δ133p53α, and Δ133p53γ and Δ133p53β isoforms. A strong correlation (0.8 > ρ > 0.6) was 
found between Δ133p53β and Δ133p53α, TAp73 and Δ133p53β and a moderate correlation (0.6 > ρ > 0.4) 
between p53γ and p53α, Δ40p53β and Δ40p53α. For other genes tested, a strong correlation was determined for 
GLI1 and Δ133p53α, and GLI1 and GLI2, a moderate correlation for NME1 and NME2, GLI2 and NME2, PTCH1 
and NME2, and PTCH1 and ΔNp73. A weak correlation (ρ < 0.4) was found between GLI2 and TAp73, and GLI3 
and ΔNp73 (Supplementary Table S2).
At the protein level, a strong correlation was detected between TAp73β and TAp73α, and TAp73β and p53α. 
The remaining correlations between p53/p73 isoforms were mostly moderate (p53α with Δ133p53β, Δ160p53α, 
TAp73α and ΔNp73α; Δ133p53α with Δ133p53β, Δ160p53α with TAp73β; Δ160p53α with TAp73α; TAp73α 
with TAp73β and ΔNp73α). Interestingly, the expression of Δ133p53β was only negatively correlated with other 
isoforms.
NME1 protein was weakly correlated with ΔNp73α, but strongly with NME2 and GLI2ΔN. A mutual corre-
lation was found between the two GLI1 isoforms, while GLI1FL isoform was negatively correlated with GLI2FL 
isoform. Unlike GLI1, where both isoforms were similarly correlated with other proteins, for the correlations 
between GLI3A and GLI3R the correlations were completely different: GLI3A correlated weakly with TAp73α 
and moderately with N′ΔGLI1, while GLI3R correlated strongly with p53α, moderately with TAp73β and weakly 
with GLI3A (Supplementary Table S3).
Accordingly, a strong correlation was found primarily between the family members, which is somehow 
expected because isoforms often share common transcriptional regulation. However, observed correlations 
between members of different families, e.g. negative correlation between GLI1 and TP53 isoforms or positive cor-
relations between either TP73 isoforms or NME2 and HH-GLI pathway genes, are much more interesting since 
they can indicate a potential interplay among those families of genes and proteins.
There was almost no correlation between gene and protein expression, with NME1 gene being the only excep-
tion showing a moderate correlation between gene and protein expression (ρ = 0.43, p = 0.031) (data not shown). 
We assume this is a consequence of using different translation initiation sites and numerous translational modi-
fications happening within p53 and GLI families of proteins.
Determination of BRAF and TP53 mutation status. Twenty out of 38 samples (52.6%) were positive 
for BRAF mutation. The most frequent BRAF mutation found in melanoma, c.1799T > A (p.V600E), was found in 
19 cases (95%), while c.1798_1799delGTinsAA (p.V600K) was found in the remaining mutation positive sample. 
This is in line with the available literature56.
Conversely, only 3 out of 30 samples were positive for TP53 mutations (Supplementary Table S4). This obser-
vation is consistent with previously studies demonstrating the mutation of TP53 locus as a rare event during 
melanomagenesis56; between 15–20% according to the cBioPortal online tool of TCGA Consortium (http://www.
cbioportal.org/).
Levels of gene/protein expression and their relation to clinicopathological characteristics. We 
analysed the association of various patients’ characteristics mutually and in relation to gene/protein expression. 
It was observed that BRAF mutation-positive patients tend to develop metastases at a younger age (median 63.5 
years vs. 69.5 years, p = 0.019) (Fig. 7a). This was in accordance with Ekedahl and colleagues who in a clinic-based 
metastatic melanoma cohort found that BRAF mutation was associated with a younger age at primary diagnosis57. 
In tumour tissue from BRAF mutation-positive patients has been noticed a trend of higher GLI3 expression 
(p = 0.058) (data not shown). Although it was found that the expression of GLI1 is higher in human primary 
melanoma harbouring BRAF p.V600E mutation58, we did not detect such correlation in our studies. Interestingly, 
tumour samples from patients who had two or more previous metastases had significantly higher Δ133p53α 
protein expression levels compared to those with only one previous metastasis (p = 0.039) (Fig. 7b). In addition, 
it was observed that location of a specific metastatic tissue has an impact on the expression of various genes and 
proteins. For instance, skin metastases had the lowest gene expression of p53α compared to metastases from 
lymph nodes or other locations (p = 0.033) (Fig. 7c). The same was observed for ΔNp73α protein (p = 0.039) 
Figure 6. Comparison of mean normalized protein expression values for tumour samples (solid line) and 
melanoma cell lines (dashed line). Protein expression was determined by densitometry and normalized to actin.
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(Fig. 7d), while the opposite trend (higher expression in skin metastases) was determined for ΔNp73 gene 
expression (p = 0.057) (data not shown). Interestingly, the expression of Δ133p53β gene was significantly lower 
in tumour samples from patients who developed subsequent metastases (p = 0.013) (Fig. 7e).
Figure 7. Association of patients’ characteristics and gene/protein expression. (a) BRAF mutation status is 
associated with age of onset (p = 0.019). (b) Occurrence of previous metastases is associated with Δ133p53α 
protein expression (p = 0.039). (c) Location of sampled tissue is associated with the expression of p53α gene 
(p = 0.033) and (d) ΔNp73α protein (p = 0.039). (e) Development of subsequent metastasis is associated with 
Δ133p53β gene expression (p = 0.013). Black rectangle represents the median value and bars represent the 
interquartile range. *Denotes p < 0.05.
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Impact of gene/protein expression and clinicopathological characteristics on patients’ survival. 
Nineteen patients (50%) died during the follow-up period. The median survival time of our patients was 19 
months. To examine the impact of clinicopathological characteristics of patients and gene/protein expression 
profiles on overall survival (OS), a univariate analysis was performed. Among all patients’ characteristics, only the 
development of new metastasis has shown to have a significant impact on OS. Interestingly, patients who did not 
develop subsequent metastases had almost four times higher chances to die compared to those with at least one 
new metastasis (hazard ratio (HR) 3.88, 95% confidence interval (CI) 1.54–9.78, p = 0.009) (Fig. 8a). Although 
counterintuitive, it could be easily assumed that those patients from the start had a more severe form of disease, 
and in consequence, did not live long enough to develop new metastases.
Furthermore, patients with high (above median value) p53α gene expression tended to live shorter compared to 
those with low p53α expression (HR 3.16, 95% CI 0.99–10.09, p = 0.037) (Fig. 8b). In addition, patients with high 
Δ133p53β gene expression had more than four times higher risk to die compared to those with low Δ133p53β 
expression (HR 4.30, 95% CI 1.16–15.98, p = 0.042) (Fig. 8c). This could be connected with patients who did not 
develop subsequent metastases which have particularly higher Δ133p53β expression (Fig. 7e), and both have a 
negative impact on OS of patients with metastatic melanoma (Fig. 8a,c). Recently, it was also shown that the elevated 
expression of Δ133p53β causes tumour cells to spread to other organs regardless of the TP53 mutation status and 
increases the risk of cancer recurrence and death in patients with breast cancer59. Therefore, it is worthwhile to fur-
ther explore the prognostic significance of this isoform as a marker for shorter OS in metastatic melanoma patients.
When we dichotomized expression data based on the receiver operating characteristic (ROC) curve anal-
yses, expression of several additional genes and one protein showed a significant impact on OS. Opposite 
to p53α, patients with low p53β gene expression had shorter OS (HR 5.36, 95% CI 1.52–18.85, p = 0.009) 
(Supplementary Fig. S2a). Few studies investigated the prognostic value of p53β and reported the associa-
tion of p53β expression with longer disease-frees survival in TP53 mutant breast cancer37; in cholangiocar-
cinoma p53β downregulation combined with Δ133p53 upregulation was associated with shorter OS38. The 
tumour suppressive role of p53β is supported with findings which show that p53β enhances both p53 and 
TAp73-mediated apoptosis60,61. Also, p53β was shown to enhance, p53-dependent transcription of p21 and 
PUMA in melanoma cell line41. Low NME1 expression was also associated with shorter OS in our cohort of 
metastatic melanoma patients (HR 3.41, 95% CI 1.15–10.11, p = 0.027) (Supplementary Fig. S2b) which is in 
accordance with its role as a metastasis suppressor. Several groups reported the correlation between low NME1 
expression and worse patient prognosis and lower overall survival15,16,45. Further support comes from the study 
where the lowest NME1 protein expression was found in primary skin melanoma samples which metasta-
sized in lymph nodes62. However, the same study also showed that there was no difference in patient survival 
between NME1 high- or low-expressing primary melanomas. On the contrary, in an animal model it was 
shown that tumours expressing low levels of NME1 mRNA had significantly reduced survival rates and times63. 
We also observed that patients with high GLI3 expression showed shorter OS compared to patients with lower 
expression, which was observed for both GLI3 gene (HR 2.88, 95% CI 1.03–8.02, p = 0.043) (Supplementary 
Fig. S2c) and GLI3R protein (HR 3.28, 95% CI 1.07–10.00, p = 0.037) (Supplementary Fig. S2d). This is in con-
trast with one previous study where it was observed that higher expression of GLI3 mRNA was associated with 
better survival of metastatic melanoma patients43.
Our study again showed that assessment of the association between continuous variables such as gene expres-
sion and survival time markedly depends on the method used for binarization of potential biomarker data64.
Conclusion
In summary, in this study we have examined a large number of isoforms of protein families involved in melanoma 
development, progression and metastasis. Gene expression has proven to be less reliable in the detection of spe-
cific isoforms, so protein levels should be examined when discussing protein activity. It has been demonstrated 
that many isoforms positively or negatively affect the activities of wild type proteins, so specific isoforms should 
be further examined to establish their role in tumour progression.
Materials and Methods
Patients. Metastatic melanoma tissues and matched adjacent healthy skin were obtained from 38 patients 
(Supplementary Table S4). All patients were treated at the Sestre milosrdnice University Hospital Center and clin-
ical data were available. The study complied with the Helsinki Declaration and was approved by the Ethics Review 
Committee of Sestre milosrdnice UHC and the Bioethical committee of Ruđer Bošković Institute. Informed con-
sent according to the World Medical Association Declaration of Helsinki was obtained from all patients. The tis-
sues were collected during surgery, frozen immediately in dry ice and stored at −80 °C until extraction. Survival 
time was measured from the date of surgery to the time of death or the last follow-up observation. The median 
follow-up of patients at the time of analysis was 16 months (range 1–38 months). The information on mortality 
was obtained from Croatian National Cancer Registry, Croatian Institute of Public Health.
RNA extraction, RT and qPCR analysis. RNA was extracted using TRIzol Reagent and/or PureLink 
RNA Mini spin columns, and reverse transcribed using High Capacity cDNA Reverse Transcription Kit accord-
ing to the manufacturers’ instructions. qPCR analysis was performed using TaqMan Gene Expression Master 
Mix and TaqMan Gene Expression Assays (all Thermo Fisher Scientific, MA, USA). Gene expression analyses 
were performed according to protocol suggested by the manufacturer on 7300 Real-Time PCR System (Thermo 
Fisher Scientific). To distinguish the different TP53 isoforms, a nested qPCR approach was used and qPCR was 
performed on CFX96 Real-Time PCR Detection System (Bio-Rad, CA, USA) using Takyon Low Rox SYBR 
MasterMix dTTP Blue (Eurogentec, Belgium). All details with primer sequences and positions are provided in 
Supplementary Materials and Methods, Tables S5 and S6, Fig. S3.
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Protein extraction and western blot analysis. Proteins were extracted from frozen tumour tissues 
and corresponding healthy skin and separated on SDS-polyacrylamide gels and transferred to nitrocellulose 
membranes (Merck Millipore, USA). The list of antibodies used and all details are available in Supplementary 
Materials and Methods. Densitometric quantification of protein levels was determined using ImageJ software 
(https://imagej.net).
Figure 8. Kaplan-Meier survival curves showing significant impact of clinicopathological characteristic and 
gene expression levels on overall survival (OS) for metastatic melanoma patients. (a) OS according appearance 
of new metastasis. (b) OS according p53α gene expression. (c) OS according Δ133p53β gene expression. Tick 
marks indicate censored cases.
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Extraction of DNA and BRAF mutation analysis. DNA was extracted from frozen tumour tissues. Exon 
15 of BRAF gene was amplified by PCR using F-TTCATGAAGACCTCACAGTAAAAA and R-CCACAAAATG 
GATCCAGACA primers. PCR products were denatured (HR-1 High-Resolution Melter, Idaho Technology, UT, 
USA) at 0.2 °C/s ramp rate and melting curves were analysed using HR-1 software. Samples with aberrant melting 
patterns were sequenced in both directions using Big Dye Terminator 1.1 Cycle Sequencing kit (Thermo Fisher 
Scientific) on ABI PRISM 310 Genetic Analyzer (Thermo Fisher Scientific).
TP53 mutation analysis. Using the RNA extracted and converted into cDNA as described above, we per-
formed the well-established yeast functional assay (FASAY) to determine the TP53 status in melanoma patients. 
The TP53 coding sequence was amplified with a two-step nested PCR using Go-Taq G2 Master Mix (Promega). 
More details are available in Supplementary Materials and Methods.
Cell culture. A panel of melanoma cell lines (A375M, CHL1, LM6 (4405 P), Mel224, Mel501, Mel505, 
WM793B and WM983B) was kindly provided by Dr. Bergamaschi (Barts and The London School of Medicine 
and Dentistry, London, UK). The cells were grown in DMEM (Sigma Aldrich, USA) or RPMI 1640 (Lonza, 
Switzerland) supplemented with 10% FBS, 1 mM sodium pyruvate (both Thermo Fisher Scientific), 1% strepto-
mycin - penicillin, and 2 mM L-glutamine (both Sigma Aldrich) and maintained at 37 °C with 5% CO2. All cell 
lines were tested to be mycoplasma free.
Statistical analysis. Is provided in Supplementary Materials and Methods.
Data Availability
All patients’ data including clinical characteristics and the results of gene and protein expressions are available as 
Supplementary Data file.
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